The Texas A&m University System

Technische Universitat Braunschweig

Universitá Degli Studi Di Pavia

Doris Meier

Magnus A Hook

Michael Hust

Ya-Ping Ko

Srishtee Arora

Federico Bertoglio

Livia Visai

The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against

Growing community of inventors

Munich, Georgia

Doris Meier